JSSH
APLS

J. Safra Sarasin Holding’s Apellis Pharmaceuticals APLS Stock Holding History

J. Safra Sarasin Holding’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-70,500
Closed -$1.6M – 502
2025
Q3 		$1.6M Sell
70,500
-45,184
-39% -$1.05M 0.03% 235
2025
Q2 		$2M Buy
115,684
+68,588
+146% +$1.27M 0.03% 217
2025
Q1 		$1.03M Sell
47,096
-13,251
-22% -$366K 0.02% 318
2024
Q4 		$1.93M Sell
60,347
-13,230
-18% -$398K 0.03% 225
2024
Q3 		$2.12M Buy
73,577
+36,034
+96% +$1.33M 0.04% 204
2024
Q2 		$1.44M Buy
+37,543
New +$1.7M 0.03% 288

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

J. Safra Sarasin Holding's APLS Position: Q4 2025 in Review

J. Safra Sarasin Holding sold out of Apellis Pharmaceuticals (APLS) in Q4 2025, closing a stake of 70,500 shares — an estimated $1.6M sold.

J. Safra Sarasin Holding first reported a position in APLS in Q2 2024 and held it in 6 quarters. The position peaked at $2.12M in Q3 2024. 279 funds tracked by Wall St. Rank hold APLS as of Q4 2025.

  • J. Safra Sarasin Holding reported no remaining Apellis Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • J. Safra Sarasin Holding sold 70,500 Apellis Pharmaceuticals shares in Q4 2025, an estimated $1.6M.
  • J. Safra Sarasin Holding first reported a position in Apellis Pharmaceuticals in Q2 2024 and held it in 6 quarters.
  • J. Safra Sarasin Holding's Apellis Pharmaceuticals position peaked at $2.12M in Q3 2024.
  • 279 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2025.

Based on J. Safra Sarasin Holding's 13F filing for Q4 2025, filed 15 Jan 2026.